Tuesday, 17 May 2022, 12:00-13:00 CET
The actual prices paid for medicines by public payers are often obscured due to the confidential discounts given by pharmaceutical companies. However, the arrival of very expensive medicines has created a push towards increasing transparency.
Net price transparency has the potential to support the affordability of pharmaceuticals and accountability of public payers. However, there are concerns that introducing net price transparency within the existing pricing system may reduce access.
Empirical evidence on the effect of NPT on access and affordability for pharmaceuticals is extremely limited, so what might happen? What are the trade-offs, impacts and challenges in introducing net price transparency?
Keynote speaker:
Erin Webb, European Observatory on Health Systems and Policies / Technical University Berlin
Speakers:
Chris Fearne, Deputy Prime Minister & Minister of Health, Malta
François Bouvy, European Federation of Pharmaceutical Industries and Associations (EFPIA)
Sabine Vogler, National Public Health Institute, Austria
Natasha Azzopardi, WHO Regional Office for Europe
Moderators:
Dimitra Panteli & Erica Richardson (European Observatory on Health Systems and Policies)